Key Points It's about to significantly expand its biologics research and manufacturing effort at a facility in Massachusetts. This should cost it a cool $70 million. 10 stocks we like better than AbbVie › The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (NYSE: ABBV) stock on Wednesday. The pharmaceutical company's shares rose by nearly 6% in value as a result, during a session when the S&P 500 (SNPINDEX: ^GSPC) crept up a compara ...

AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Dividend Aristocrat Stocks to Invest in Right Now. AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability Photo by Dan Dennis on Unsplash AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that manufactures and markets innovative medicines. The demand for drugs is so stable that the industry is considered highly defensive, with little economic exposure. Even in recessions, doctors continue to prescribe treatments and patients cont ...

AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating ABBV a “Buy” or “Strong Buy” and price targets suggesting further upside. Today’s Featured Stock Valued at $394 billion, AbbVie (ABBV) has become one of the top-most phar ...

Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center of excellence for biologics research and development and manufacturing. This expansion is part of the company's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand criti ...

Key Takeaways AbbVie has submitted an FDA application for tavapadon to treat Parkinson's disease.TEMPO studies showed tavapadon improved symptoms across a broad Parkinson's disease population.If approved, tavapadon would be AbbVie's second recent Parkinson's therapy clearance.AbbVie (ABBV) announced that it has submitted a regulatory filing with the FDA, which seeks approval for its investigational drug tavapadon as a once-daily oral treatment for Parkinson’s disease (PD).The FDA filing is supported by resu ...

Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets Continue Reading AbbVie ...

AbbVie (NYSE:ABBV) said that when its ovarian cancer treatment Elahere launches in the UK, its list price will be the same as it is in the US. The wholesale acquisition cost of Elahere (mirvetuximab soravtansine), which was approved in ...

AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S. ...

Core Insights - AbbVie has been increasing its dividend annually for over 50 years, qualifying it as a Dividend King, including the years prior to its split with Abbott Labs [1] - The focus on dividend-paying companies is emphasized as a strategy for achieving high risk-adjusted long-term returns, highlighting the importance of both stable high dividends and their growth [1] Company Analysis - AbbVie is recognized for its consistent dividend growth, which is foundational for long-term investment strategies [1] - The company’s approach to dividends is seen as a critical factor in attracting and retaining investors, particularly those focused on income generation [1] Investment Strategy - The analysis encourages a deep examination of companies, particularly those with strong dividend policies, to enhance investment processes and knowledge [1]

Core Viewpoint - President Trump announced a 100% tariff on pharmaceutical products entering the US starting October 1st unless companies establish manufacturing plants in the US, with the EU and Japan exempt from this tariff [1] Group 1: Market Reaction - The pharmaceutical sector is responding positively to the news, with stocks of major pharmaceutical companies trading higher [2] - This tariff announcement is perceived as a "d-risking event" for the pharmaceutical industry, alleviating investor uncertainty since the initial tariff announcement on April 2nd [3] Group 2: Manufacturing Plans - Many pharmaceutical companies have already announced plans to increase manufacturing in the US, which may mitigate the impact of the tariffs [4] - A comprehensive list of companies that have made public commitments to expand manufacturing includes major players in both the US and Europe, indicating a proactive approach to the new tariff environment [5] Group 3: Future Investments - Companies in the pharmaceutical sector typically have long-term plans (5 to 10 years) for capital expenditures and manufacturing growth, which may have been accelerated due to the tariff announcement [7] - There is an expectation that new manufacturing plants will begin construction soon, reflecting a genuine commitment to increasing domestic production [8]